<DOC>
	<DOCNO>NCT00251745</DOCNO>
	<brief_summary>The purpose study assess efficacy safety daily treatment Dexlansoprazole modify release ( MR ) ( 60 mg 90 mg daily [ QD ] ) compare placebo QD relief daytime nighttime heartburn 4 week subject gastroesophageal reflux disease ( GERD ) .</brief_summary>
	<brief_title>Efficacy Safety Dexlansoprazole Modified Release Formulation Treat Heartburn</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , multicenter , placebo-controlled , 3-arm study 4 week treatment period . This study compare efficacy daily Dexlansoprazole MR ( 60 mg 90 mg ) placebo administer orally single daily dose morning , breakfast . The study design evaluate symptom relief subject symptomatic non-erosive GERD . Approximately 450 subject enrol approximately 120 U.S. potentially ex U.S. site . The study consist two period ; screen period , last minimum 7 day maximum 21 day , treatment period , last 4 week . Because development plan Dexlansoprazole MR revise , result 2 identical study , T-GD04-082 ( post , NCT00241745 ) T-GD04-083 ( NCT00251758 ) , combine analyzed single large study refer study T-GD04-082 . A total 908 subject include combined analysis ; 416 subject enrol Study T-GD04-082 492 subject enrol Study T-GD04-083 .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Subjects NonErosive Gastroesophageal Reflux Disease identify main symptom heartburn . History episodes heartburn 6 month longer prior screening . History episodes heartburn 4 day 7 day prior Day 1 record electronic diary . Use prescription nonprescription proton pump inhibitor ( PPIs ) , histamine ( H2 ) receptor antagonist , sucralfate , misoprostol prokinetics throughout study· Use antacid ( except study supply Gelusil® ) . Use drug significant anticholinergic effect . Need continuous anticoagulant ( blood thinner ) therapy . Endoscopic Barrett 's esophagus and/or definite dysplastic change esophagus . History dilatation esophageal stricture , Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) . Current historical evidence ZollingerEllison syndrome hypersecretory condition . History gastric , duodenal esophageal surgery except simple oversew ulcer . Acute upper gastrointestinal ( UGI ) hemorrhage within 4 week screen endoscopy . Erosive Esophagitis see endoscopy study screen . Coexisting disease affect esophagus . Abnormal laboratory value suggest significant clinical disease . Known acquired immunodeficiency syndrome ( AIDS ) Females pregnant lactating . History Alcohol abuse . History Cancer within 3 year prior screen . Chronic ( &gt; 12 dos per month ) use nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor Subjects , opinion investigator , unable comply requirement study unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Non-Erosive Gastroesophageal Reflux Disease ( GERD )</keyword>
	<keyword>Heartburn</keyword>
</DOC>